[Juvenile idiopathic arthritis. II. Treatment and prognosis].
Immunosuppressants, including methotrexate and more recently anti-TNFalpha, have modified the prognosis of the most severe forms juvenile idiopathic arthritis. However, the therapeutic management is still challenging and adjuvant therapies, including physiotherapy, surgery, or even bisphosphonates and growth hormone, are still widely used to limit the negative impact of an extended general corticotherapy.
Quartier
Pierre
P
Unit d'immunologie-hématologie et rhumatologie pédiatriques, Centre de référence national labellisé Arthrites juvéniles, hôpital Necker-Enfants malades, 75743 Paris. quartier@necker.fr
Prieur
Anne-Marie
AM
D000293:Adolescent; D001171:Arthritis, Juvenile / Q000150:complications / Q000628:therapy*; D002648:Child; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D011379:Prognosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha